449 results about "Single-domain antibody" patented technology

The invention provides a cyclic single-chain trispecific antibody against human tumor. It comprises three parts. The first part is an anti-tumor Fab antibody, an anti-tumor single-domain antibody or an scFv. The second part is a reshaped Fab antibody against human CD3, a reshaped single-domain antibody against human CD3 or a reshaped scFv against human CD3. The third part is a reshaped Fab antibody against human CD28, a reshaped single-domain antibody against human CD28 or a reshaped scFv against human CD28. The present invention also offers the DNA sequence coding for this trispecific antibody, expression vectors containing this DNA sequence and host cells (E. coli) containing the vectors.

The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.

The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and / or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.

The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.

The invention discloses humanized single-domain antibodies for a novel coronavirus SARS-CoV-2 and an application of the humanized single-domain antibodies. The invention protects the single-domain antibodies described in any one of SEQ ID No.1 to SEQ ID No.5. Experimental results show that the single-domain antibodies provided by the invention have good affinity with receptor binding domain (RBD)antigens and have high neutralization activity on SARS-CoV-2 pseudovirus. The humanized single-domain antibodies have important scientific significance and application prospect for prevention and clinical treatment of the new coronavirus SARS-CoV-2 and for development of diagnostic reagents of the new coronavirus SARS-CoV-2.

The present invention relates to antibodies directed to Epidermal Growth Factor Receptor that are single domain antibodies Camelidae VHHs. It further relates to methods of of use of said polypeptides.

The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with CD3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scFvs, Fabs, di-scFvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments. In one embodiment, a multi-specific polypeptide binds both a T-cell receptor complex on T-cells and a tumor antigen to induce target-dependent T-cell cytotoxicity, activation and proliferation.

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.

The present invention relates to polypeptides comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3 domain, gpIb and / or collagen, homologues of said polypeptides, and / or functional portions of said polypeptides, for the treatment for conditions which require a modulation of platelet-mediated aggregation and which overcomes the problems of the prior art. A further aspect of the invention is methods of production of said polypeptides, methods to coat devices with such polypeptides used in medical procedures (e.g. PCTA, stenting), methods and kits for screening for agents that modulate platelet-mediated aggregation and kits for the diagnosis of diseases related to platelet-mediated aggregation.

The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and / or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation. It further relates to protocols for screening for agents that modulate the Epidermal Growth Factor Receptor, and the agents resulting from said screening. The invention further a method for delivering therapeutic molecules to the interior of cells.

Disclosed is the use of an antagonist of Interleukin 1 receptor type 1 (IL-1R1) for the manufacture of a medicament treating, preventing or suppressing lung inflammation or a respiratory disease. In some embodiments of the described invention, the medicament is for local administration to pulmonary tissue. Also disclosed are methods for treating lung inflammation or a respiratory disease.

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Epidermal Growth Factor Receptor. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation. It further relates to protocols for screening for agents that modulate the Epidermal Growth Factor Receptor, and the agents resulting from said screening. The invention further a method for delivering therapeutic molecules to the interior of cells

The invention relates to a recombinant single chain tri-specific antibody, and it is characterized by that it is made by successively connecting antibody of antineoplastic related antigen, FC onnecting peptide, antihuman CD3 antibody, HSA connecting peptide and antihuman CD28 antibody. More specifically, said invention relates to a recombinant single chain tri-specific antibody; CEA-TsAb of anti-CEA, anti-CD3 and anti-CD28. Said antibody is made up by using three antibody fragments (unti-CEA single chain antibody, anti-CD3 single chain antibody and anti-CD28 single chain antibody), utilizing two connecting peptides (FC connecting peptide and HSA connecting peptide) and series-connecting them together, and on its C end C-myc tag and (His)6-tag are added. Said invention also relates to a method for constructing expressing and purifying said antibody, including exonic DNA sequence of said antibody, expression vector and host cell containing said vector.

The invention is related to a recombinant single-chain tri-specific antibody made from anti-Tumor Associated Antigen (TAA) antibody, FC interlinker, anti-CD3 antibody, HSA interlinker and anti-CD28 antibody in turn. Particularly, the invention relates to an anti-CEA, anti-CD3, anti-CD28 recombinant single-chain tri-specific antibody, CEA-scTsAb, which was constructed with three tandem antibody fragments (anti-CEA scFv, anti-CD3 scFv and anti-CD28 single-domain antibody) linked by two interlinkers (FC interlinker, HSA interlinker), and could be appended by C myc tag or histidine tag ((His)6-tag) at the C terminal. It also concerns a method for construction, expression and purification of the antibody. It also offers the encoded DNA sequence of the antibody, expression vectors and host cells for the vectors.

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to interferon gamma. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the IFN-gamma receptor, and the agents resulting from said screening.

Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses.

In some aspects, polypeptides comprising single domain antibodies and methods of identifying single domain antibodies are provided. In some embodiments polypeptides comprising a single domain antibody and a sortase recognition sequence, are provided. In some aspects, products and methods of use in modulating the immune system, e.g., modulating an immune response, are provided.

Methods and systems for increasing stability of a target polypeptide in a serum are described. The methods and systems utilize a fusion protein comprising a single-domain antibody against a serum albumin (SASA), the target polypeptide and optionally a linker. The fusion protein has a significantly prolonged serum half life in comparison with the target polypeptide alone. The SASA fusion tag also facilitates the expression and purification of the fusion protein. This allows direct in vivo screening or utilization of the target polypeptide for its biological activity or efficacy regardless of its intrinsic serum half life, which has significantly increased the number of candidates for the development of novel protein based diagnosis or treatment.

The invention discloses an immunofluorescence detection test strip and a preparation method thereof for rapid quantitative detection of porcine epidemic diarrhea viruses. The test strip comprises a sample cushion, a combination cushion, a chromatography film and a water-absorbing cushion, wherein the combination cushion is provided with a fluorescent microsphere labelled anti-PEDV (Porcine Epidemic Diarrhea Viruses) single-domain antibody; the single-domain antibody has high specificity and high sensibility against the antigen PEDV. The test strip is used for detecting PEVD viruses in breeding pig manure or PEDV pollution in feeding stuff plasma proteins on the basis of the newfound immunology principle of the specific single-domain antibody and antigen, can be used for on-site rapid detection or laboratory detection by simply taking 5-10 min; when the test strip is used in combination with a fluorescence quantitative detector, quantitative detection can be realized; the test strip is simple and convenient to operate, operators don't need professional training, a special laboratory is not needed, the limitation of the conventional detection method is overcome, and the test strip has good market prospects.

The invention discloses a VEGF (Vascular Endothelial Growth Factor) single-domain antibody as well as a fusion antibody and a polymer antibody of the VEGF antibody. The invention also discloses a nucleotide sequence for encoding the antibodies, an expression vector containing the nucleotide sequence, a recombinant bacterium containing the nucleotide sequence as well as a preparation method and applications of the antibodies. The VEGF antibody is low in molecular weight, high in plasticity and wide in application prospect.

The invention relates to a chimeric antigen receptor (CAR) and application thereof. The CAR comprises BCMA (B-cell maturation antigen) binding structural domains, transmembrane structural domains, oneor a plurality of co-simulation structural domains and intracellular signal transduction structural domains. The BCMA binding structural domains comprise heavy chain complementary determining regionsHCDR 1-3, and amino acid sequences of the HCDR 1-3 are sequentially shown as SEQ ID NO:1-3.

The invention relates to a novel coronavirus SARS-Cov-2 resistant neutralizing single-domain antibody and application thereof. The antibody at least has one of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3, and can be used for preparing diagnostic reagent or diagnostic kit, an antibody medicine or medicinal composition against COVID-19. The novel coronavirus SARS-Cov-2 resistant neutralizing single-domain antibody is obtained through a phage display technology, can stop combination of the SARS-Cov-2-RBD and ACE2 positive cells, has a remarkable virus neutralizing effect on SARS-Cov-2pseudovirion, and provides an efficient backup antibody medicine for COVID-19 prevention and treatment.

The invention discloses a bactrian camel heavy-chain (HC) variable-domain antibody resisting a porcine circovirus 2 as well as a preparation method and an application thereof, and belongs to the field of a biotechnology. A PCV2 (Porcine Circovirus Virus) inactivated vaccine immunized bactrian camel is firstly utilized and a phage display technology is utilized to establish a PCV2 immune VHH antibody base; and a high-specificity variable domain antibody of heavy chains of HCAbs (VHH) which has a good affinity with the PCV, particularly a PCV2 virus antigen; and the antibody disclosed by the invention has an amino acid sequence shown as SEQ (sequence) ID NO.1 or an amino acid sequence which is shown as SEQ ID NO.2 and has the sequence isogeny being more than 95%. The PCV2 heavy-chain variable-domain antibody disclosed by the invention has the very important meanings on researching porcine circovirus, particularly researching a porcine circovirus 2-type infection mechanism and establishing rapid antigen detection with high sensitivity and specificity or diagnosing a reagent.

The invention provides an antibodies that bind to KDR with an affinity comparable to or higher than human VEGF, and that neutralizes activation of KDR. Antibodies include whole immunoglobulins, monovalent Fabs and single chain antibodies, multivalent single chain antibodies, diabodies, triabodies, and single domain antibodies. The invention further provides nucleic acids and host cells that encode and express these antibodies. The invention further provides a method of neutralizing the activation of KDR, a method of inhibiting angiogenesis in a mammal and a method of inhibiting tumor growth in a mammal.

The invention discloses a CD 38 single-domain antibody and its coding gene, a CD38 immunotoxin and, preparation method, expression vector and use in a drug for treating multiple myeloma and chronic lymphoid leukemia and a host cell. Through a single-domain antibody-immunotoxin fusion technology, the CD38 immunotoxin is obtained. The CD38 immunotoxin has the advantages of simple processes, low cost and high tumor cell targeting killing efficiency and is based on the CD 38 single-domain antibody. The CD38 immunotoxin is conducive to multiple myeloma and chronic lymphoid leukemia treatment.